Although Socioeconomic status (SES), race/ethnicity, and surgical type/delays are associated with breast cancer mortality outcomes, studies on these associations have been contrasting. This study examined the racial/ethnic and SES differences in surgical treatment types and delays. Also, we quanti ed the extent to which these differences explained the racial/ethnic disparities in breast cancer mortality. MethodsWe studied 290,066 women 40 + years old diagnosed with breast cancer between 2010 and 2017 identi ed from the Surveillance, Epidemiology, and End Results database. We performed logistic regression models to examine the association of SES and race/ethnicity with surgical treatment type and delays. We performed mediation analysis models to quantify the extent to which mortality differences were mediated by treatment, sociodemographic, and clinicopathologic factors. ResultsNon-Hispanic (NH) Black [Odds ratio (OR) = 1.16, 95% CI: 1.13-1.19] and Hispanic women [OR = 1.27, 95% CI: 1.24-1.31] were signi cantly more likely to undergo mastectomy compared to NH White women. Similarly, NH Black and Hispanic women had higher odds of delayed surgical treatment than NH Whites.Patients in the highest SES quintile, compared to those in lowest the lowest, were less likely to experience breast cancer-speci c mortality (BCSM). Variations in treatment, SES, and clinicopathological factors signi cantly explained 70% of the excess BCSM among NH Blacks compared to their NH White counterparts. ConclusionsBridging the gap of access to adequate healthcare services for all to diminish the disproportionate burden of breast cancer would require a multifactorial approach that addresses several biological and social factors that cause these differences.This retrospective cohort study used data from the Surveillance, Epidemiology, and End Results (SEER) research plus 18 registries' specialized census tractlevel SES and rurality dataset released in November 2020. SEER is a cancer surveillance program supported by the National Cancer Institutes (NCI) that serves as the primary source of reliable incidence and survival data in the US. [21]. A detailed database and data collection description can be found elsewhere [21].The study subjects were de-identi ed, and there was no patient contact; thus, the study was exempted from an Institutional Review Board's (IRB) approval.We use SEER*stat version 8.4.0 and identi ed 403,791 women, 40 years old or older, diagnosed with breast cancer as the rst primary cancer between January 2010 and December 2017. From the 403,791 women, our study only included patients who underwent surgery and excluded those who were not recommended for surgery, declined recommended surgery, or had unknown surgery status. In addition, we excluded patients with distant tumor stages, grade IV tumors, and those diagnosed during an autopsy. Lastly, we excluded patients with unknown breast cancer subtypes, tumor grade, tumor stage, tumor site, race, SES, marital status, or rurality. Hence, the sample size used in our analysis was ...
<abstract><sec> <title>Backgrounds</title> <p>Data on the association between comorbid diabetes mellitus (DM) and acute pancreatitis (AP) remains limited. Utilizing a large, nationwide database, we aimed to examine the impact of comorbid diabetes mellitus on patients admitted for acute pancreatitis.</p> </sec><sec> <title>Methods</title> <p>This was a retrospective case-control study of adult patients with AP utilizing the National Inpatient Sample from 2015–2018, using ICD–10 codes. Hospitalization outcomes of patients admitted for AP with comorbid DM were compared to those without comorbid DM at the time of admission. The primary outcome was a mortality difference between the cohorts. Multivariable-adjusted cox proportional hazards model analysis was performed. Data was analyzed as both sex aggregated, and sex segregated.</p> </sec><sec> <title>Results</title> <p>940,789 adult patients with AP were included, of which 256,330 (27.3%) had comorbid DM. Comorbid DM was associated with a 31% increased risk of inpatient mortality (aOR: 1.31; p = 0.004), a 53% increased risk of developing sepsis (aOR: 1.53; p = 0.002), increased hospital length of stay (LOS) (4.5 days vs. 3.7 days; p < 0.001), and hospital costs ($9934 vs. $8486; p < 0.001). Whites admitted for AP with comorbid DM were at a 49% increased risk of mortality as compared to Hispanics (aOR: 1.49; p < 0.0001). Different comorbidities had sex-specific risks; men admitted for AP with comorbid DM were at a 28% increased risk of mortality (aOR: 1.28; p < 0.0001) as compared to women. Men with comorbid DM plus obesity or hypertension were also at increased risk of mortality as compared to women, whereas women with comorbid DM plus renal failure were at greater risk of mortality as compared to men.</p> </sec><sec> <title>Conclusions</title> <p>Comorbid DM appears to be a risk factor for adverse hospitalization outcomes in patients admitted for AP with male sex and race as additional risk factors. Future prospective studies are warranted to confirm these findings to better risk stratify this patient population.</p> </sec></abstract>
Background: Background: The literature regarding the efficacy and safety of non-anti-TNF biologics in hospitalized patients with refractory Acute Severe Ulcerative Colitis (ASUC) remains limited. Methods: We systematically reviewed articles reporting outcomes on non-anti-TNF biologics for patients with refractory ASUC. Pooled analysis was performed using a random-effects model. Results: An estimate of 41.3%, 48.5%, 81.2%, and 36.2% of patients in clinical remission showed a clinical response and were colectomy-free, and steroid free, respectively, all in 3 months. 15.7% and 8.2% of patients had adverse events or infections, respectively. Conclusion: Non-anti-TNF biologics appear safe and effective therapeutic options for hospitalized patients with refractory ASUC.
Background and Aims: Multiple myeloma (MM) is a plasma cell dyscrasia that is common among patients with autoimmune diseases. However, the association between ulcerative colitis (UC) and multiple myeloma (MM) is yet to be established. We aimed to evaluate the prevalence of MM among patients with UC in the United States. Methods: This cross-sectional cohort analysis used the National Inpatient Sample from 2015–2018 to assess the overall MM prevalence among patients with and without UC, and within specific demographic subgroups. Prevalences were compared using a logistic regression model controlling for sex and age. Results: The crude prevalence of MM among patients with UC (n = 1750) compared with patients without UC (n = 366,265) was 0.44% vs. 0.37%, respectively. Patients with UC had increased overall odds of having MM (odds ratio (OR), 1.26). Males with UC had higher prevalence of MM (53.7% vs. 46.3%, respectively) than females. Patients with UC and MM were more likely to be African American than White (15.6% vs. 9.2%, respectively). Patients with UC age >64 had a higher prevalence of MM than those aged below 65 (70.9% vs. 29.1%, respectively). Patients with UC who were obese (BMI > 30) had a higher prevalence of MM than those who were non-obese (12.6% vs. 8.3%). Conclusions: Overall, UC appears to be associated with MM. This association can be particularly observed in specific demographic groups, such as obese, African American males, or patients >64 years of age. Thus, a high degree of clinical suspicion for MM is warranted, even with minimal symptomatology, in patients with UC, in particular among elder, obese, and African American males.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.